Novavax Ranks #129 on Deloitte’s Technology Fast 500™

Rockville, MD (December 11, 2012) – Novavax, Inc. (Nasdaq: NVAX) today announced it has been named to Deloitte's Technology Fast 500™. The Fast 500 is the pre-eminent technology awards program in North America (U.S. and Canada) recognizing technological innovation, entrepreneurship and rapid growth. The 2012 Deloitte Technology Fast 500™ is based on the fastest revenue growth during the period from 2007 through 2011. The ranking includes both public and private companies.

"It’s an honor for all of us at Novavax that Deloitte has recognized our organization as one of the fastest growing technology companies in North America,” said Stanley C. Erck, Novavax President and Chief Executive Officer. “This recognition wouldn’t be possible without the commitment to innovative vaccine development that is embodied through the entire Novavax team.”

On December 3, Deloitte Fast 500™ honorees gathered at NASDAQ Marketsite for the ringing of the bell at the closing of the market. Pictured here are Novavax President and Chief Executive Officer Stanley C. Erck, right, & Senior Vice President and Chief Medical Officer Gregory M. Glenn, M.D.
About Deloitte's 2012 Technology Fast 500™
The Deloitte Technology Fast 500 is the pre-eminent technology awards program in North America (U.S. and Canada) with 2012 being its eighteenth anniversary. Combining technological innovation, entrepreneurship and rapid growth, Fast 500 companies – large, small, public, and private – span a variety of industry sectors, and are leaders in hardware, software, telecom, semiconductors, life sciences and emerging areas, such as clean technology. These companies are on the cutting edge and are transforming the way we do business today.

The Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Technology Fast 500 web site, and public company database research conducted by Deloitte Services LP. Technology Fast 500 award winners for 2012 are determined based on percentage fiscal year revenue growth during the period from 2007 to 2011. The ranking includes both public and private companies.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biopharmaceutical company creating vaccines to address a broad range of infectious diseases worldwide. Using innovative recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea and PATH. Together, these organizations support Novavax’ worldwide commercialization strategy and have the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company’s website, www.novavax.com.

###